AGENAgenus Inc.Finished
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
Metastatic Pancreatic Ductal Adenocarcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 81 (final count)
- Started
- Mar 27, 2023
- Main results expected
- Jan 5, 2026
- Fully finished
- Jan 5, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival as Assessed by Investigator
Measured over: Up to 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05630183 · record last updated 2026-06-11 · checked 2026-11-09 15:47 UTC